Stocklytics Platform
Acumen Pharmaceuticals
ABOS46
$0.98arrow_drop_down8.63%-$0.09
NASDAQ - As of Apr 4, 2:25 PM EDT Market Open
Penny Stock
ABOS46

$0.98

arrow_drop_down8.63%

Performance History

no data available for performance history chart

There's no data available for performance history chart

no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Stocklytics logo

Period: Next 12 Months

Predicted: just now

info

Analyzed by 12 Wall Street experts, Acumen Pharmaceuticals's 12-month projections average at $14.66, spanning from a high of $22.00 to a low of $8.00. This signifies an 1,395.07% shift from the current price of $0.98.

Analyst Ratings

Buy

Buy
6
100.00%
Hold
0
0.00%
Sell
0
0.00%
Ratings from: April

Last updated: just now

Total: 6
info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

Price$788.17
Perf. (24h)arrow_drop_down0.11%-$0.91
Market Cap$708.73B
Price$538.05
Perf. (24h)arrow_drop_down0.45%-$2.44
Market Cap$494.34B
Price$159.39
Perf. (24h)arrow_drop_down0.39%-$0.62
Market Cap$397.30B
Price$199.86
Perf. (24h)arrow_drop_down0.88%-$1.77
Market Cap$356.69B

About Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals, Inc. (ABOS) is a biopharmaceutical company that focuses on the development of innovative treatments for neurodegenerative diseases. The company's primary goal is to improve patients' quality of life by delivering groundbreaking therapies that target the underlying causes of these debilitating conditions. With a strong pipeline of potential drug candidates and a dedicated team of experts, Acumen Pharmaceuticals is well-positioned to make a significant impact in the field of neuroscience.
ABOS stock has shown promising performance in recent years, reflecting the market's confidence in the company's potential. The stock price history of Acumen Pharmaceuticals reveals a steady upward trend, with occasional fluctuations due to market dynamics. Investors seem to have recognized the value of the company's research and development efforts, leading to a positive trajectory for the stock.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Daniel J. O'Connell M.B.A.
Headquarters
Charlottesville
Employees
39
Exchange
NASDAQ
add Acumen Pharmaceuticals to watchlist

Keep an eye on Acumen Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Acumen Pharmaceuticals's (ABOS) price per share?

The current price per share for Acumen Pharmaceuticals (ABOS) is $0.99. The stock has seen a price change of -$0.09 recently, indicating a -8.64% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Acumen Pharmaceuticals (ABOS)?

For Acumen Pharmaceuticals (ABOS), the 52-week high is $5.09, which is 415.18% from the current price. The 52-week low is $0.98, the current price is 0.3% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Acumen Pharmaceuticals (ABOS) a growth stock?

Acumen Pharmaceuticals (ABOS) has shown an average price growth of -1.65% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Acumen Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Acumen Pharmaceuticals (ABOS) stock price performance year to date (YTD)?

As of the latest data, Acumen Pharmaceuticals (ABOS) has a year-to-date price change of -42.56%. Over the past month, the stock has experienced a price change of -14.09%. Over the last three months, the change has been -48%. Over the past six months, the figure is -58.66%.
help

Is Acumen Pharmaceuticals (ABOS) a profitable company?

Acumen Pharmaceuticals (ABOS) has a net income of -$52.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$61.14M. Furthermore, the EBITDA is -$92.84M.
help

What is the market capitalization of Acumen Pharmaceuticals (ABOS)?

Acumen Pharmaceuticals (ABOS) has a market capitalization of $59.85M. The average daily trading volume is 1, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level